The single-use bioprocessing market size is estimated to reach $21.7 billion by 2027 and is furthermore poised to grow at a CAGR of 17.6% over the forecast period of 2022-2027. Single-use bio-processors are designed to accommodate only once, and moreover, they are being produced using plastic components which in turn get sealed and then sterilized using gamma radiation in the pre-commercial stages, which are- preclinical, clinical, and biopharmaceutical manufacturing. More than >85% of the participants are using such technologies. The process, including cell culture, is now being predominantly handled by using single-use bioprocessing. The process efficiency can be significantly ramped up by using such technologies. Filtration assemblies are now being tried to get re-combined with SUS or Single-use technology. Disposable mixers are now implanted within the disposable technology. The earlier technology was dominated by stainless-steel processors but owing to the character advantages over the former, the following has been readily adopted. Owing to low requirements of sterilizing and cleaning and the automation of processes with the use of IoT and AI have been identified as the key factors driving the Single-use bioprocessing industry forward in the projected period of 2022-2027.
Report Coverage
The report: “Single-Use Bioprocessing Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Single Use Bioprocessing Market.
By Product Type- Filtration Assemblies, Media Bags and Containers, Disposable Single Use Bio processors, Disposable Mixers, and Others.
By Workflow- Upstream, Fermentation, and Downstream.
By End Users – Academia and Research Centers, Pharmaceutical and Biotechnology Companies, and Contract Research Organization.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).
Key Takeaways
- Geographically, North America’s Single-Use Bioprocessing Market held a dominant market share in the year 2021. It is owing to an increase in the R&D pertaining activities coupled with the growing demand for new drugs, which are in turn increasing the participants in the pre-commercial stages. However, Asia-Pacific is set to offer lucrativ e to the marketers as the region is seeing expanding clinical research activities and pro-actively launching drugs to address the pandemic needs and others.
- The benefits over the former technologies such as equipment come sterile, allowing avoidance of cleaning, sterilization, and validation of sterilization prior to usage has been a leading factor driving the market forward. However, costs pertaining to bags and their short life while in the middle of processes have been seen as the major challenge for the market.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Single-Use Bioprocessing market report.
Single-use Bioprocessing Market- Geography (%) for 2021
Single-use Bioprocessing Market Segmentation Analysis- By Product Type
The single-use bioprocessing market based on the product type can be further segmented into Filtration Assemblies, Media Bags and Containers, Disposable Single Use Bio processors, Disposable Mixers, and Others. Disposable Single Use Bio processors held a dominant market share in the year 2021. It is owing to the mutilative benefits it offers to the end-users. More so, the single-use bio processors allow the small factories to operate at a cost-friendly nature and even follow a greener processing regimen. Additionally, manufacturers have noticed the difference and efficiency of the time it takes to start operations. For example, in a stainless-steel facility, one will have to incur 2 or 2.5 years between the start of the facility and the day one starts to produce material. However, the following timeline can be cut in half when adopting a greenfield facility such as discussed.
Moreover, disposable single-use bio processors are estimated to be the fastest-growing, with a CAGR of 18.4% over the forecast period of 2022-2027. It is owing to the cost set up which is required. The physical footprint of the plant which uses this is 30%. Additionally, around 90% of water can be saved when using the following type.
Single-use Bioprocessing Market Segmentation Analysis- By End Users
The single-use bioprocessing market segment is based on end-user Academia and Research Centers and Pharmaceutical and Biotechnology Companies, and Contract Research Organization. Pharmaceutical and biotechnology held a dominant market share in the year 2021. It is owing to the robust adoption of single-use bio processor technology by the major drug and pharma giants in the last decade. For example, WuXi Application Technology, have now built around 16 production bioreactors of a capacity between 1,000 liters or 2,000-liter scale.
However, Contract Research Organization is estimated to be the fastest-growing, with a CAGR of 18.7% over the forecast period of 2022-2027. It is owing to the various benefits it offers over the former model. Additionally, the invention behind the single-use processor was to save costs; by outsourcing such activities, the companies can save even further amounts. Moreover, favorable policies in the outsourced countries have allowed future growth.
Single-use Bioprocessing Market Segmentation Analysis- By Geography
The Single-Use Bioprocessing Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s Single-Use Bioprocessing held a dominant market share of 41% as compared to the other regions. It is owing to the ready deployment of funds by both government and private players to enhance the already existing infrastructure. For example, Pfizer has now announced a single bioreactor use operational plan in Massachusetts. Additionally, USA and Canada allow new players to enter the said market. The government of Canada announced CAD 275 million (EUR 179 million) for the R&D activities related to antivirals, diagnostics, vaccines, and clinical trials for COVID-19.
However, Asia-Pacific is set to grow at a lucrative growth opportunity to the marketers in the projected period of 2022-2027. It is owing to favorable policies governed by the various countries. For example, China and India are now allowing a heavy inflow FDIs. Lastly, India allotted a 137% increase in healthcare development in the year 2021.
Single-use Bioprocessing Market Drivers
The increasing demand for biopharmaceutical has readily allowed for the growth of the market
Biopharmaceutical industry has been gaining momentum in the past decade, more so due to advent of various chronic illnesses globally. As per the UN association, by the year 2020, there were around 727 million people above the age 65+, and the numbers are to reach 1.5 billion by 2050. But even before that, on the country level, various economies are facing the pressure of geriatric population, such as the U.S. The efficiency of single-use systems allows clinicians to perform multiple different trials of various drugs. More so, with the earlier bioprocessing unit of 20,000 liters, manufacturers were bounded to only allow one drug tests. The growing demand within the drug discovery have allowed the market growth.
The growing demand being noticed in the pre-commercial scale has allowed the growth of market
As far as >85% of the given manufacturers or drug discoverers are using SUS or single-use bioprocessing units. Additionally, the contract manufacturers prefer the following technology as it uses less space, and equipment come sterile which allows the avoidance of cleaning, sterilization, and validation of sterilization prior to usage. Currently in the US, around 4,000 trials were going on which were in early Phase-1 trial. Additionally, as per various surveys conducted by researchers, some of the notable benefits which it offers to the bio-manufacturers are it decreases the risk of cross product contamination, eliminates the need for cleaning and lastly, reduces the capital investment which is required to get the factory up and running.
Single-use Bioprocessing Market Challenges
Costs pertaining to bags and their short life while in the middle of processes have been seen as the major challenge for the market
As per various independent researchers, certain potential drawbacks were noticed and even highlighted to the product manufacturers. For example, every three in four respondents felt that the bags broke in the middle of the process and the product material spelt. Moreover, every two in four participants felt the problems pertaining to leachable and extractable. Contamination takes place owing to the oozing of leachable. Lastly, around 68% of the said population said that the expected the cost of the SUS bags to go low, as owing to its usage frequency the costs at times level with the old stainless steel processing units.
Single-use Bioprocessing Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the single-use bioprocessing Market. The top 10- single-use bioprocessing market companies are-
- Sartorius Stedim Biotech S.A
- Thermo Fisher Scientific
- Danaher Corporation
- Merck KGaA
- Getinge AB
- Eppendorf AG
- Corning
- Entegris
- Avantor
- CESCO Bioengineering Co. Ltd.
Recent Developments
- In August 2021, PBS recently closed its funding round of $10 million which would allow the expansion of internal operations and increase in the technology. The investor for the same was Broad Oak Capital. The company uses vertical wheel technology, which it believes is superior than traditional stir tank mixer used for the production of therapeutics.
- In December 2020, Thermo Fischer Scientific announced the launch of its Single-Use Bio-Reactor which would help in cell culture production. Moreover, the bio-reactor has proved to deliver improved performance and scalability when the large cultures have to be processed. Lastly, the reactor is infused with TruBio software which is powered by the Delta-V automation platform.
Relevant Titles
Large- and Small-Scale Bioprocessing Market- Forecast (2022-2027)
Report Code- HCR 18452
Disposable Medical Devices Market- Forecast (2022-2027)
Report Code- HCR 0050
For more Lifesciences and Healthcare Market reports, please click here
